Showing 4451-4460 of 7279 results for "".
- Do Physicians Mention Sunscreen Use Often Enough at Patient Visits?https://practicaldermatology.com/news/20130905-do_physicians_mention_sunscreen_use_often_enough_at_patient_visits/2459468/
- Novan Awarded Contract by BARDA to Develop a Medical Countermeasure for Thermal Burnshttps://practicaldermatology.com/news/20130829-novan_awarded_contract_by_barda_to_develop_a_medical_countermeasure_for_thermal_burns/2459472/
- FDA Approves Valchlor Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type CTCLhttps://practicaldermatology.com/news/20130826-fda_approves_valchlor_gel_for_the_treatment_of_stage_ia_and_ib_mycosis_fungoides-type_ctcl/2459475/
- Iagnosis, Inc., Launches Mobile App for DermatologistOnCall®https://practicaldermatology.com/news/20130815-iagnosis_inc_launches_mobile_app_for_dermatologistoncall/2459479/A new app for an online dermatology platform has recently launched from Iagnosis, Inc. The DermatologistOnCall® app, based on the website www.dermatologistoncall.com, enables to create an account and submit photographs and descriptions of their condition. Patients then receive a response from a boar
- Alma Lasers to Present New Technologies at AAD Meetinghttps://practicaldermatology.com/news/20130227-alma_lasers_to_present_new_technologies_at_aad_meeting/2459604/Alma Lasers unveiled its two latest technologies, the vShape focused radiofrequency (RF) workstation and the ClearLift. The RF workstation addresses tailored anti-aging treatments for the face, body, and cellulite. The ClearLift is Q-switched technology penetrates deep beneath the skin and decreases
- Direct-to-Consumer Pharmaceutical Advertising: Minimizing Risks?https://practicaldermatology.com/news/20120912-letter_to_editor_discusses_changes_in_direct-to-consumer_pharmaceutical_advertising/2459741/When prescription drugs switch to over-the-counter status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC), potentially leading to reduced focus on warnings about risks and side effects, a new report suggests. While the FDA regulates prescription drug advertisi
- FDA Extends Action Date For Tofacitinib New Drug Application By Three Monthshttps://practicaldermatology.com/news/20120824-us_food_and_drug_administration_extends_action_date_for_tofacitinib_new_drug_application_by_three_months/2459748/
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic pati
- Psoriasis Genetic Map Explored by International Psoriasis Councilhttps://practicaldermatology.com/news/20120607-psoriasis_genetic_map_explored_by_international_psoriasis_council/2459788/The International Psoriasis Council (IPC) is leading the effort to establish collaboration among leading geneticists and dermatologists to advance the understanding of the genetic basis of psoriasis. Their
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w